Ahmedabad based Intas Pharmaceuticals Limited has informed the share market(BSE/NSE) that they have planning to enter capital markets with its public issue of 5810000 equity shares of Rs 10 each. The company has filed a Draft Red Herring Prospectus (DRHP) with market regulator Securities and Exchange Board of India (SEBI) for the same. The premium to be decided via 100% book building process. The IPO price band has not been decided yet. The company would raise Rs 425 crore through this IPO. Intas Pharmaceuticals Limited engages in the manufacture and marketing of medications for chronic and acute medical conditions in India.The company product list consists tablets, capsules, injectables, parenterals, cytotoxic formulations, and drug delivery systems in the areas of central nervous system, cardiovascular, diabetology, gastroenterology, urology, pain management, ophthalmology, and therapeutics, as well as animal health care, oncology, and biotechnology.
The proceeds of the IPO amount would be used by the company for repayment/ prepayment of term loan; capital expenditures towards existing manufacturing facilities; investment in EHS infrastructure; and investment in corporate R&D center.
The shares are proposed to be listed on the Bombay Stock Exchange Limited (BSE) and the National Stock Exchange of India Limited (NSE).
The Book Running Lead Managers to the issue are Kotak Mahindra Capital Company and Morgan Stanley India Company Pvt Limited.
Registrar of the Issue : Bigshare Services Private Linited, Mumbai.
Stay tuned to BelltheBull Blog for more on Intas Pharma IPO !Google+